H2S/butyrate imbalance drives enteric alpha-synuclein pathology via TLR4 signaling

Target: SNCA Composite Score: 0.000 Price: $0.50 Citation Quality: Pending Parkinson's disease Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
2
Opposing
Quality Report Card click to collapse
F
Composite: 0.000
Top 50% of 1512 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.72 Top 33%
B+ Evidence Strength 15% 0.72 Top 19%
B+ Novelty 12% 0.78 Top 30%
A Feasibility 12% 0.82 Top 20%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
5 supporting | 2 opposing
Citation quality: 43%
Debates
2 sessions C+
Avg quality: 0.50
Convergence
0.00 F 3 related hypothesis share this target

From Analysis:

Gut Microbiome Analysis in Parkinson's Disease

How does the gut microbiome composition differ between PD patients and healthy controls, and which microbial metabolites correlate with motor and non-motor symptoms?

→ View full analysis & debate transcript

Description

In Parkinson's disease, elevated H2S-producing Desulfovibrio species and depleted butyrate-producing Faecalibacterium prausnitzii create a metabolite imbalance that simultaneously disrupts gut barrier integrity and increases systemic LPS translocation. The resulting TLR4 activation on enteric neurons triggers NF-κB-mediated neuroinflammation, promoting local alpha-synuclein misfoldling and aggregation. This enteric pathology then propagates bidirectionally along the vagus nerve to the dorsal motor nucleus and from autonomic ganglia to peripheral neurons, representing the gut-first progression of PD.

...

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.72 (15%) Evidence 0.72 (15%) Novelty 0.78 (12%) Feasibility 0.82 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.000 composite
7 citations 7 with PMID 5 medium Validation: 43% 5 supporting / 2 opposing
For (5)
5
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
2
MECH 4CLIN 1GENE 2EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Monogenic Parkinson's Disease: Genotype, Phen…SupportingGENEGenes (Basel) MEDIUM2022-PMID:35328025-
SNCA REP1 and Parkinson's disease.SupportingMECHNeurosci Lett MEDIUM2018-PMID:29859327-
Parkinson's disease - genetic cause.SupportingGENECurr Opin Neuro… MEDIUM2023-PMID:37366140-
SNCA-AS1 in aging and Parkinson's disease.SupportingMECHAging (Albany N… MEDIUM2022-PMID:35438650-
Mitochondria and Parkinson's Disease: Clinica…SupportingCLINJ Parkinsons Di… MEDIUM2021-PMID:33074190-
Strain-specific effects of Desulfovibrio on neurod…OpposingMECH- MODERATE--PMID:40790298-
TLR4/NF-κB neuroinflammation from gut dysbiosis in…OpposingMECH- MODERATE--PMID:41694373-
Legacy Card View — expandable citation cards

Supporting Evidence 5

Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing. MEDIUM
Genes (Basel) · 2022 · PMID:35328025
SNCA REP1 and Parkinson's disease. MEDIUM
Neurosci Lett · 2018 · PMID:29859327
Parkinson's disease - genetic cause. MEDIUM
Curr Opin Neurol · 2023 · PMID:37366140
SNCA-AS1 in aging and Parkinson's disease. MEDIUM
Aging (Albany NY) · 2022 · PMID:35438650
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. MEDIUM
J Parkinsons Dis · 2021 · PMID:33074190

Opposing Evidence 2

Strain-specific effects of Desulfovibrio on neurodegeneration show that not all H2S-producing Desulfovibrio st… MODERATE
Strain-specific effects of Desulfovibrio on neurodegeneration show that not all H2S-producing Desulfovibrio strains enhance alpha-synuclein aggregation equally; the variability in outcomes indicates that factors beyond H2S production (e.g. specific lipopolysaccharide structures) are responsible, challenging the H2S-centric mechanism
TLR4/NF-κB neuroinflammation from gut dysbiosis in Parkinson's is activated more potently by bacterial lipopol… MODERATE
TLR4/NF-κB neuroinflammation from gut dysbiosis in Parkinson's is activated more potently by bacterial lipopolysaccharides than by H2S; the proposed H2S/butyrate balance as the primary TLR4 driver is not experimentally distinguished from co-occurring LPS-mediated activation in PD gut microbiome studies
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Hypotheses: Gut Microbiome in Parkinson's Disease

Hypothesis 1: Butyrate-Producing Bacteria Depletion Drives Motor Impairment Through Enteric Nervous System Energy Failure

Description: The loss of butyrate-producing bacteria (particularly Roseburia intestinalis, Faecalibacterium prausnitzii, and Coprococcus catus) in PD patients creates a localized energy deficit in enteric neurons. Butyrate serves as the primary energy substrate for colonic epithelial cells and enteric neurons through β-oxidation. This energy failure compromises neuronal protein clearance mechanisms,

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation: Gut Microbiome-Parkinson's Disease Hypotheses

Preliminary Assessment

These hypotheses are sophisticated and internally coherent. However, several suffer from a common structural weakness: they conflate correlative associations with mechanistic causality, use mechanistic vocabulary to describe correlative observations, and lack falsification plans that could meaningfully distinguish between causes and consequences of PD pathology. I will address each systematically.

Hypothesis 1: SCFA-Depleted Microbiome Drives Microglial TREM2 Dysfunction

Weaknesses

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Practical Feasibility Assessment: Surviving Gut Microbiome-PD Hypotheses

Preliminary Remarks

The critical evaluation identified H1, H2, and H3 as partially surviving but significantly weakened. H5, H6, and H7 were not addressed in the critique and retain their original confidence scores. I will assess all six remaining hypotheses, prioritizing those with the strongest combination of mechanistic plausibility, existing therapeutic leads, and tractable clinical endpoints.

Assumed survival threshold: Hypotheses with revised/original confidence ≥0.60, and those with direct therapeutic

Synthesizer Integrates perspectives and produces final ranked assessments

{
"ranked_hypotheses": [
{
"title": "SIBO Contributes to Levodopa Metabolism and Motor Fluctuations",
"description": "Small intestinal bacterial overgrowth (SIBO), prevalent in 25-50% of PD patients, creates a bacterial reservoir where bacteria possess aromatic amino acid decarboxylase activity. These bacteria metabolize levodopa to dopamine before it reaches the CNS, reducing bioavailability and contributing to motor fluctuations. SIBO severity correlates with daily 'off' time, and specific bacterial taxa (particularly Lactobacillus species) predict variable drug response.

Price History

0.490.500.51 0.52 0.48 2026-04-262026-04-262026-04-26 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (7)

SNCA REP1 and Parkinson's disease.
Neuroscience letters (2018) · PMID:29859327
No extracted figures yet
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.
Journal of Parkinson's disease (2021) · PMID:33074190
No extracted figures yet
No extracted figures yet
No extracted figures yet
Parkinson's disease - genetic cause.
Current opinion in neurology (2023) · PMID:37366140
No extracted figures yet
No extracted figures yet
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
5

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.050

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure
Score: 0.650 | neurodegeneration
Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization
Score: 0.571 | neurodegeneration
Sulfated glycans and metal-binding CSF proteins brace alpha-synuclein fibril polymorphs
Score: 0.489 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 SNCA — PDB 1XQ8 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Gut Microbiome Analysis in Parkinson's Disease

neurodegeneration | 2026-04-16 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)